title: Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia.
abstract: BACKGROUND
  Alemtuzumab is highly effective at treating chronic lymphocytic leukemia (CLL) in bone marrow, which is the usual site of residual disease after fludarabine-based treatment. Eliminating residual disease potentially is associated with longer remission and overall survival. The authors of this report evaluated the ability of subcutaneous alemtuzumab to treat residual disease.
  
  
  METHODS
  Patients in partial remission (PR), nodular PR (nPR), or complete remission (CR) who had disease in bone marrow established by 2-color flow cytometry analysis were enrolled and received alemtuzumab 30 mg subcutaneously 3 times weekly for 4 weeks, and patients had the option to self-administer alemtuzumab. Responders were patients in PR who converted to an nPR or a CR, patients in nPR who converted to a CR, and patients in CR who had no evidence of disease on 2-color flow cytometry analysis after treatment.
  
  
  RESULTS
  There were 31 patients enrolled, of whom 29 were evaluable, and there were 23 responders (4 of 4 patients who achieved a CR, 8 of 9 patients who achieved an nPR, and 11 of 16 patients who achieved a PR. Nonresponders had significantly lower plasma alemtuzumab levels at the end of treatment. Furthermore, higher plasma alemtuzumab levels at the end of treatment were correlated with a longer response duration. Compared with the results from an historic group that received intravenous alemtuzumab for residual disease, there was a trend toward a higher response rate but a shorter response duration with subcutaneous alemtuzumab.
  
  
  CONCLUSIONS
  The current results demonstrated that self-administered, subcutaneous alemtuzumab was safe and active for residual disease and that plasma alemtuzumab levels and real-time minimal residual disease evaluation are important endpoints to monitor in future alemtuzumab consolidation trials.
authors.affiliation: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Kipps
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Keating
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Brown
authors.forename: John G
authors.initials: JG
authors.lastname: Gribben
authors.forename: Mary
authors.initials: M
authors.lastname: Browning
authors.forename: Laura Z
authors.initials: LZ
authors.lastname: Rassenti
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Greaves
authors.forename: Donna
authors.initials: D
authors.lastname: Neuberg
authors.forename: Susan M
authors.initials: SM
authors.lastname: O'Brien
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000740:Anemia / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab
references.citation: Leukemia. 2004 Jun;18(6):1093-101
references.pmid: 15071604
references.citation: J Clin Oncol. 2005 May 1;23(13):2971-9
references.pmid: 15738539
references.citation: Blood. 2004 Aug 15;104(4):948-55
references.pmid: 15090452
references.citation: Br J Haematol. 2009 Jan;144(1):95-8
references.pmid: 19016732
references.citation: Leukemia. 2007 May;21(5):956-64
references.pmid: 17361231
references.citation: Blood. 2002 May 15;99(10):3554-61
references.pmid: 11986207
references.citation: J Immunol Methods. 2002 Feb 1;260(1-2):285-302
references.pmid: 11792397
references.citation: J Clin Oncol. 2005 Sep 10;23(26):6325-32
references.pmid: 16155015
references.citation: J Clin Oncol. 2006 May 20;24(15):2337-42
references.pmid: 16618945
references.citation: J Clin Oncol. 2007 Dec 10;25(35):5616-23
references.pmid: 17984186
references.citation: Blood. 2002 Aug 1;100(3):768-73
references.pmid: 12130484
references.citation: Br J Cancer. 1977 Jan;35(1):1-39
references.pmid: 831755
references.citation: Blood. 2008 Feb 15;111(4):1816-9
references.pmid: 18039954
references.citation: Cancer. 2003 Dec 15;98(12):2657-63
references.pmid: 14669286
references.citation: J Clin Oncol. 2009 Aug 20;27(24):3994-4001
references.pmid: 19597025
references.citation: Blood. 2002 Dec 15;100(13):4609-14
references.pmid: 12393534
references.citation: Blood. 2008 Aug 15;112(4):975-80
references.pmid: 18411418